Human medicines European public assessment report (EPAR): Livmarli, Maralixibat chloride, Date of authorisation: 09/12/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Leflunomide ratiopharm, leflunomide, Date of authorisation: 28/11/2010, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Altuvoct, efanesoctocog alfa, Date of authorisation: 28/06/2024, Status: Authorised

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 July 2024

Human medicines European public assessment report (EPAR): Invega, paliperidone, Date of authorisation: 24/06/2007, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Dimethyl fumarate Mylan, dimethyl fumarate, Date of authorisation: 22/04/2024, Status: Authorised

Transferring a veterinary marketing authorisation

Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 16, Status: Authorised

Q&A clinic on Product Management Service (PMS) Product User Interface - 20 June 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 June 2024, 15:00 (CEST) to 20 June 2024, 15:30 (CEST)

Q&A clinic on Product Management Service (PMS) Product User Interface - 13 June 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 June 2024, 15:00 (CEST) to 13 June 2024, 15:30 (CEST)